Latest news

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new distribution partner in China. The order relates to sampling NLAB Saga® to pharmaceutical manufacturers.  “This order is a result of our production now being stable. Going forward we will have larger volumes of our silica products, which is why we are now increasing our sales efforts in China. We will continue to handle many customers ourselves, but also work

Nanologica has received a supplementary order for the company’s silica-based purification media NLAB Saga® from a customer in the US who placed an initial order of approximately SEK 1.3 million in June. The customer is a manufacturer of peptide drugs and the order relates to evaluation of NLAB Saga® on a production scale. In June, Nanologica received a first order from this customer in the US for evaluation of the company’s silica on a production

Nanologica has entered the insulin market in China with an order of approximately SEK 2 million for the company’s silica-based purification media NLAB Saga®. The customer is an insulin manufacturer and the order relates to evaluation of NLAB Saga® on a production scale. This is Nanologica’s first order regarding evaluation of NLAB Saga® for insulin manufacturing on the Chinese market. Nanologica’s team has worked with this customer for a few years and the customer has

Nanologica’s CEO Andreas Bhagwani presents at Redeye Theme: Tools and Supplies in Life Science on September 23. The time for the presentation is 9.35.  

The number of registered shares and votes in Nanologica AB has changed during the month of June following the registration of exercised warrants of series TO5. In 2024, Nanologica issued a total of 11,044,654 warrants of series TO5 within the framework of a rights issue of units. During the period May 7, 2025 to May 21, 2025, holders of warrants of series TO5 have had the right to subscribe for shares by virtue of warrants.